
CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (I):



Formula (I),

or a pharmaceutically acceptable salt thereof wherein:

B is selected from a 7- to 15-membered heterocycle and C_7-C_{15} carbocycle, wherein the 7- to 15-membered heterocycle and C_7-C_{15} carbocycle are each optionally substituted with one or more substituents independently selected from halogen, -CN, -NO_2, =O, -$N(R^{21})_2$, -$B(OR^{21})_2$, -OR^{21}, -SR^{21}, -$S(O)_2(R^{21})$, -$S(O)_2N(R^{21})_2$, -$NR^{21}S(O)_2R^{21}$, -$C(O)N(R^{21})_2$, -$C(O)NR^{21}OR^{21}$, -$N(R^{21})C(O)R^{21}$, -$N(R^{21})C(O)N(R^{21})_2$, -$N(R^{21})C(O)OR^{21}$, -$C(O)R^{21}$, $C(O)OR^{21}$, -$OC(O)R^{21}$, -$OC(O)N(R^{21})_2$, C_{1-6} alkyl-$N(R^{20})_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, C_{1-6} cyanoalkyl, C_{1-6} haloalkyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_3-C_{12} carbocycle and 5- to 12-membered heterocycle;

R^1 is selected from hydrogen and 5- to 15-membered heterocycle, wherein the 5- to 15-membered heterocycle is optionally substituted with one or more substituents independently selected from halogen, -$B(OR^{20})_2$, -OR^{20}, -SR^{20}, -$S(O)_2(R^{20})$, -$S(O)_2N(R^{20})_2$, -$S(O)N(R^{20})_2$, -$S(O)R^{20}(=NR^{20})$, -$NR^{20}S(O)_2R^{20}$, -$C(O)N(R^{20})_2$, -$C(=NR^{20})N(R^{20})_2$, -C_{1-6} alkyl$(=NOR^{20})$, -$C(O)NR^{20}OR^{20}$, -$N(R^{20})C(O)R^{20}$, -$N(R^{20})C(O)N(R^{20})_2$, -$N(R^{20})C(O)OR^{20}$, -$N(R^{20})_2$, -$C(O)R^{20}$, -$C(O)OR^{20}$, -$OC(O)R^{20}$, -$OC(O)N(R^{20})_2$, -NO_2, =O, $=N(R^{20})$, $=NO(R^{20})$, -CN, -NHCN, C_{1-6} alkyl-$N(R^{20})_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, C_{1-6} cyanoalkyl, C_{1-6} haloalkyl, C_{1-6} alkyl-SO_2R^{20}, C_{1-6} alkoxyalkyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_3-C_{12} carbocycle and 5- to 12-membered heterocycle, wherein the C_3-C_{12} carbocycle and 5- to 12-membered heterocycle are each optionally substituted independently with one or more R^{1*};

each R^{1*} is independently selected from halogen, $-B(OR^{20})_2$, $-OR^{20}$, $-SR^{20}$, $-S(O)_2(R^{20})$, $-S(O)_2N(R^{20})_2$, $-S(O)N(R^{20})_2$, $-S(O)R^{20}(=NR^{20})$, $-NR^{20}S(O)_2R^{20}$, $-C(O)N(R^{20})_2$, $-C(O)NR^{20}OR^{20}$, $-N(R^{20})C(O)R^{20}$, $-N(R^{20})C(O)N(R^{20})_2$, $-N(R^{20})C(O)OR^{20}$, $-N(R^{20})_2$, $-C(O)R^{20}$, $-C(O)OR^{20}$, $-OC(O)R^{20}$, $-OC(O)N(R^{20})_2$, $-NO_2$, =O, $=N(R^{20})$, $=NO(R^{20})$, -CN, -NHCN, C_{1-6} alkyl-$N(R^{20})_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, C_{1-6} cyanoalkyl, C_{1-6} haloalkyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_3-C_{12} carbocycle;

Y is -O-;

R^2 is selected from heterocycle, -L-heterocycle, -L-$N(R^{23})_2$, and -L-aryl, wherein the heterocycle, and the heterocycle portion of -L-heterocycle are each optionally substituted with one or more R^6, and wherein the aryl of the -L-aryl is optionally substituted with one or more R^7;

R^3 is selected from hydrogen, halogen, -CN, $-NO_2$, $-N(R^{20})_2$, $-OR^{20}$, $-SR^{20}$, $-S(O)_2(R^{20})$, $-S(O)_2N(R^{20})_2$, $-S(O)N(R^{20})_2$, $-S(O)R^{20}(=NR^{20})$, $-NR^{20}S(O)_2R^{20}$, $-C(O)N(R^{20})_2$, $-N(R^{20})C(O)R^{20}$, $-N(R^{20})C(O)N(R^{20})_2$, $-N(R^{20})C(O)OR^{20}$, $-C(O)R^{20}$, $-C(O)OR^{20}$, $-OC(O)R^{20}$, $-OC(O)N(R^{20})_2$, C_{1-6} alkyl-$N(R^{20})_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, C_{1-6} cyanoalkyl, C_{1-6} haloalkyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_3-C_{12} carbocycle and 5- to 12-membered heterocycle;

each R^4 is independently selected from halogen, $-NO_2$, =O, =S, -CN, C_{1-6} alkyl, C_{2-6} alkynyl, C_{1-6} alkyl-$N(R^{20})_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} cyanoalkyl, C_{1-6} hydroxyalkyl, and C_{1-6} haloalkyl;

n is selected from 0, 1, 2, 3, and 4;

each R^5 is independently selected from hydrogen and C_1-C_6 alkyl;

each R^6 is independently selected from halogen, hydroxy, C_1-C_3 hydroxyalkyl, C_1-C_3 alkyl, oxo, C_1-C_3 haloalkyl, C_1-C_3 alkoxy, cyano, $=CH_2$, =NO-C_1-C_3 alkyl, C_1-C_3 aminoalkyl, $-N(R^5)S(O)_2(R^5)$, -Q-phenyl, -Q-phenylSO_2F, -NHC(O)phenyl, - NHC(O)phenylSO_2F, C_1-C_3 alkyl substituted pyrazolyl, -C_1-C_3 alkyl-$N(R^5)_2$, $-C(O)N(R^5)_2$, -C_1-C_3 alkyl-$N(R^5)_2$, $-C(O)N(R^5)_2$, tert-butyldimethylsilyloxyCH_2-, $-N(R^5)_2$, (C_1-C_3 alkoxy)C_1-C_3 alkyl-, (C_1-C_3 alkyl)C(=O), oxo, (C_1-C_3 haloalkyl)C(=O)-, $-SO_2F$, (C_1-C_3 alkoxy)C_1-C_3 alkoxy, $-CH_2OC(O)N(R^5)_2$, $-CH_2NHC(O)OC_1$-C_6 alkyl, $-CH_2NHC(O)N(R^5)_2$, $-CH_2NHC(O)C_1$-C_6 alkyl, $-CH_2$(pyrazolyl), $-CH_2NHSO_2C_1$-C_6 alkyl, $-CH_2OC(O)$heterocycle, $-OC(O)N(R^5)_2$, $-OC(O)NH(C_1$-C_3 alkyl)O(C_1-C_3 alkyl), $-OC(O)NH(C_1$-C_3 alkyl)O(C_1-C_3 alkyl)phenyl(C_1-C_3 alkyl)$N(CH_3)_2$, $-OC(O)NH(C_1$-C_3 alkyl)O(C_1-C_3 alkyl)phenyl, -OC(O)heterocycle, -O-C_1-C_3

alkyl, -S(O)$_2$(R^{20}), -S(O)$_2$N(R^{20})$_2$, -S(O)N(R^{20})$_2$, -S(O)R^{20}(=NR^{20}), -NR^{20}S(O)$_2$$R^{20}$, and -CH$_2$heterocycle, wherein the phenyl of -NHC(O)phenyl and -OC(O)NH(C_1-C_3 alkyl)(C_1-C_3 alkyl)phenyl are optionally substituted with one or more substituents selected from -C(O)H and OH, and wherein the alkyl of -O-C_1-C_3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxy; and wherein the heterocycle of -CH$_2$heterocyclyl is optionally substituted with oxo;

each Q is selected from a bond, S, and O;

each R^7 is independently selected from halogen, hydroxy, HC(=O)-, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 hydroxyalkyl, -C_1-C_3 alkyl-N(R^5)$_2$, -C(O)N(R^5)$_2$, and -N(R^5)$_2$;












each L is independently selected from a C_1-C_4 alkylene optionally substituted with one or more substituents independently selected from halogen, hydroxy, C_{1-6} alkoxy, C_1-C_4 hydroxyalkyl, C_1-C_4 alkyl, C_3-C_6 carbocycle, and 3- to 8-membered heterocycle, wherein the C_3-C_6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO$_2$, =O, =S, -CN, C_{1-6} alkyl-N(R^{20})$_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, C_{1-6} haloalkyl; and wherein optionally two substituents on the same carbon atom of L come together to form a C_3-C_6 carbocycle or 3- to 8-membered heterocycle, wherein the C_3-C_6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, -OH, -NO$_2$, =O, =S, -CN, C_{1-6} alkyl-N(R^{20})$_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, and C_{1-6} haloalkyl;













each R^{20} is independently selected from hydrogen; and C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-12} carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO$_2$, -NH$_2$, -N(C_{1-6} alkyl)$_2$, C_{1-10} alkyl, -C_{1-10} haloalkyl, -O-C_{1-10} alkyl, oxo, C_{3-12} carbocycle, and 3- to 12-membered heterocycle;









each R^{21} is independently selected from hydrogen; and C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-12} carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, -NO$_2$, -NH$_2$, -N(C_{1-6} alkyl)$_2$, C_{1-10} alkyl, -C_{1-10} haloalkyl, -O-C_{1-10} alkyl, oxo, C_{3-12} carbocycle, and 3- to 12-membered heterocycle; and

each R^{23} is independently selected from hydrogen; and C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-12} carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, $-NO_2$, $-NH_2$, $-N(C_{1-6}\text{ alkyl})_2$, C_{1-10} alkyl, $-C_{1-10}$ haloalkyl, $-O-C_{1-10}$ alkyl, oxo, C_{3-12} carbocycle, and 3- to 12-membered heterocycle.

2. The compound or salt of claim 1, wherein B is selected from an optionally substituted 7- to 11-membered fused heterocycle, wherein B has at least one sulfur atom.

3. The compound or salt of claim 2, wherein B is selected from , , , , , , , , , , and , each of which is optionally substituted with one or more optional substituents independently selected at each occurrence from halogen, C_1-C_3 alkyl, $-NH_2$, and -CN.


4. The compound or salt of claim 1, wherein B is selected from , , , , , , , , , , , ,



















5. The compound or salt of claim 1, wherein R^3 is selected from hydrogen, halogen, -CN, -NO_2, -$S(O)_2(R^{20})$, -$S(O)_2N(R^{20})_2$, -$S(O)N(R^{20})_2$, -$S(O)R^{20}(=NR^{20})$, -$NR^{20}S(O)_2R^{20}$, -$C(O)N(R^{20})_2$, -$N(R^{20})C(O)R^{20}$, -$N(R^{20})C(O)N(R^{20})_2$, -$N(R^{20})C(O)OR^{20}$, -$C(O)R^{20}$, -$C(O)OR^{20}$, -C_{1-6} alkyl-$N(R^{20})_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, C_{1-6} cyanoalkyl, C_{1-6} haloalkyl, C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl.


6. The compound or salt of claim 5, wherein R^3 is selected from hydrogen, fluorine, and -CN.


7. The compound or salt of claim 1, wherein each L is independently selected from an optionally substituted C_1-C_4 alkylene; and wherein optionally two substituents on the same carbon atom of L come together to form a C_3-C_6 carbocycle or 3- to 8-membered heterocycle, wherein the C_3-C_6 carbocycle and 3- to 8-membered heterocycle are each optionally substituted with one or more substituents selected from halogen, -OH, -NO_2, =O, =S, -CN, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, and C_{1-6} haloalkyl.


8. The compound or salt of claim 1, wherein Y-R^2 is selected from ,

















9. The compound or salt of claim 1, wherein Y-R^2 is selected from ,










, and .






10. The compound or salt of claim 1, wherein R^1 is selected from 8- to 10-membered heterocycle, wherein the 8- to 10-membered heterocycle is optionally substituted with one or more substituents independently selected from halogen, $-OR^{20}$, $-S(O)_2(R^{20})$, $-C(O)N(R^{20})_2$, $-C_{1-6}$ alkyl($=NOR^{20}$), $-C(O)R^{20}$, =O, -CN, -NHCN, C_{1-6} alkyl-$N(R^{20})_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, C_{1-6} cyanoalkyl, C_{1-6} haloalkyl, C_{1-6} alkyl-SO_2R^{20}, C_{1-6} alkoxyalkyl, C_{1-6} alkyl, C_{2-6} alkynyl, and 5- to 12-membered heterocycle, wherein the 5- to 12-membered heterocycle are each optionally substituted independently with one or more R^{1*};




and wherein each R^{1*} is independently selected from halogen, $-OR^{20}$, $-N(R^{20})_2$, $-NO_2$, =O, $=N(R^{20})$, $=NO(R^{20})$, -CN, -NHCN, C_{1-6} alkyl-$N(R^{20})_2$, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, C_{1-6} cyanoalkyl, C_{1-6} haloalkyl, and C_{1-6} alkyl.


11. The compound or salt of claim 10, wherein R^1 is , optionally substituted with one or more substituents independently selected from halogen, $-S(O)_2(R^{20})$, $-C(O)N(R^{20})_2$, $-C_{1-6}$ alkyl($=NOR^{20}$), $-C(O)R^{20}$, =O, and 5- to 9-membered heterocycle, wherein the 5- to -membered heterocycle are each optionally substituted independently with one or more R^{1*}.


12. The compound or salt of claim 1, wherein R^1 is selected from ,


, , , , ,


, , , , ,

, , and .





13. The compound or salt of claim 1, wherein R^1 is selected from .





14. The compound or salt of claim 1, wherein R^1 is .




15. The compound or salt of claim 1, wherein R^1 is .















16. The compound or salt of claim 1, wherein R^1 is .















17. The compound or salt of claim 1, wherein the compound is selected from














, , , ,
















, , , ,













, , ,















,

,

,

,

,

,

,

,

,

,

,

,

,

,
















,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,















,

,

,

,

,

,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt of any one thereof.
















18. A pharmaceutical composition comprising the compound or salt of claim 1, or a compound selected from , , , , , , , , , , , 


,

,

,

,

,

,

,

,

,

,

,

,

.


,

,

,

,

,

,

,

,

,

,

,

,

,

,













,















,

,

,

,

,

,

,

,

,

,

,

,

,
















,

,

,

,

,

,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt of any one thereof; and














a pharmaceutically acceptable excipient.
















19. Use of the pharmaceutical composition of claim 18, or a compound or salt selected from


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

.


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt of any one thereof, in the manufacture of a medicament for treating a disease or disorder, wherein the medicament is to be administered to a subject in need thereof,.

20. The use of claim 19, wherein the disease or disorder is a KRas G12D or other G12 mutants-associated cancer.

21. The use of claim 19, wherein the disease or disorder is a cancer selected from:

Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma;

Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma;

Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma);

Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma);

Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;

Biliary tract: gall bladder carcinoma, ampullary carcinoma, cholangiocarcinoma;

Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors;

Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma);

Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous


cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma);


Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma);


Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and


Adrenal glands: neuroblastoma.


22. The use of claim 19, wherein the disease or disorder is a cancer, wherein the cancer is non-small cell lung cancer, small cell lung cancer, colorectal cancer, rectal cancer or pancreatic cancer; or wherein the cancer is a tumor cancer.


23. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.


24. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.


25. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.


26. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.


27. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.


28. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.


29. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.

30. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.

31. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.

32. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.

33. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.

34. The compound or salt of claim 1, wherein the compound is , or a pharmaceutically acceptable salt of any one thereof.

35. The compound or salt of claim 1 for use as a medicament.